Our top pick for
Entera Bio Ltd is a biotechnology business based in the US. Entera Bio shares (ENTX) are listed on the NASDAQ and all prices are listed in US Dollars. Entera Bio employs 19 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$3.23|
|52-week range||$1.00 - $6.60|
|50-day moving average||$5.32|
|200-day moving average||$3.45|
|Wall St. target price||$12.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.05|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-23)||N/A|
|1 month (2021-07-02)||-47.90%|
|3 months (2021-05-03)||-4.44%|
|6 months (2021-01-30)||N/A|
|1 year (2020-07-30)||N/A|
|2 years (2019-07-30)||N/A|
|3 years (2018-07-30)||N/A|
|5 years (2016-07-30)||N/A|
|Gross profit TTM||$156,000|
|Return on assets TTM||-40.46%|
|Return on equity TTM||-187.8%|
|Market capitalisation||$122.2 million|
TTM: trailing 12 months
There are currently 178,800 Entera Bio shares held short by investors – that's known as Entera Bio's "short interest". This figure is 74.4% down from 697,102 last month.
There are a few different ways that this level of interest in shorting Entera Bio shares can be evaluated.
Entera Bio's "short interest ratio" (SIR) is the quantity of Entera Bio shares currently shorted divided by the average quantity of Entera Bio shares traded daily (recently around 8.9 million). Entera Bio's SIR currently stands at 0.02. In other words for every 100,000 Entera Bio shares traded daily on the market, roughly 20 shares are currently held short.
However Entera Bio's short interest can also be evaluated against the total number of Entera Bio shares, or, against the total number of tradable Entera Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Entera Bio's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Entera Bio shares in existence, roughly 10 shares are currently held short) or 0.0131% of the tradable shares (for every 100,000 tradable Entera Bio shares, roughly 13 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Entera Bio.
Find out more about how you can short Entera Bio stock.
We're not expecting Entera Bio to pay a dividend over the next 12 months.
Over the last 12 months, Entera Bio's shares have ranged in value from as little as $1 up to $6.6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Entera Bio's is 1.7112. This would suggest that Entera Bio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Entera Bio Ltd. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.